32results about "Angiogenesic factors" patented technology

The present invention relates to the treatment of infectious diseases. In this study, we identify potential defense mechanisms involved in maintaining brain vascular integrity during bacterial infection and perform RNA analysis of primary endothelial cells isolated from human skin (HDMEC) or brain (HBMEC) microvessels. The cells were either uninfected or infected with Neisseria meningitidis in vitro. We found 40 genes, especially ANGPTL4, that are specifically regulated in brain endothelial cells during infection. In the context of sepsis, ANGPTL4 was found to be the main barrier stabilizing protein with a defensive effect against bacterial infection. ANGPTL4 (or derived peptides) also showed potential as an adjunctive therapy to reduce bacteria-induced vascular dysfunction and mortality. Thus, the present invention relates to peptides derived from the protein ANGPTL4 and their use in the treatment of infectious diseases.

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

The present disclosure relates to an siRNA for inhibiting the expression of an angiopoietin-like protein 3 (ANGPTL3) gene, an siRNA conjugate, and a pharmaceutical composition thereof, and a method for reducing the expression of the ANGPTL3 gene by using the siRNA, the siRNA conjugate, and the pharmaceutical composition thereof. The siRNA, the siRNA conjugate, and the pharmaceutical composition thereof of the present disclosure can be used for treating and / or preventing an ANGPTL3 gene-mediated disease or disorder.

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistema magna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

The present invention provides a novel blood-derived growth-factor-containing composition. The present invention for solving the above problem is a method for preparing a growth-factor-containing composition from blood, the method comprising a step for separating platelet-rich plasma that does not contain a buffy coat component from the blood, and a step for adding citric acid and / or a salt thereof to the blood or a processed product thereof.

The present invention relates to productive tissue repair and regeneration, and in particular poylpeptides, compositions including said polypeptides, and methods of using said polypeptides or compositions for productive tissue repair and regeneration. In one aspect, the invention provides a polypeptide comprising, consisting essentially of or consisting of a C-terminal portion of NAMPT comprising a truncated cytokine finger motif (cif) motif. In another aspect, the present invention provides a fusion protein comprising, consisting essentially of or consisting of a polypeptide of a full length NAMPTcif or truncated variants and a tissue delivery or retention enhancing moiety.

The invention provides a growth factor-dextran conjugate as well as a preparation method and application thereof, the growth factor-dextran conjugate consists of a growth factor and dextran, and is obtained by coupling an amino group of the growth factor and a hydroxyl group of the dextran through a chemical reaction; the growth factor-dextran conjugate can protect the growth factor to enhance the stability of the growth factor, reduce the degradation of the growth factor in vivo and prolong the in vivo half-life period of the growth factor; coupled dextran can be combined with a cell surface receptor to promote cellular uptake of growth factors and enhance the effective action concentration of the growth factors in cells, has good biocompatibility and biological safety, and has wide application in research and development of drugs for wound repair and / or treatment of neurodegenerative diseases.

The present invention relates to the field of nucleic acid editing, in particular the field of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. In particular, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The present invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing) comprising the proteins or fusion proteins of the present invention, or nucleic acid molecules encoding them. The present invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using complexes comprising the proteins or fusion proteins of the present invention.

Disclosed herein are immunogenic compositions having a circular RNA encoding a VEGF polypeptide. Also provided herein are related methods of manufacture and therapeutic uses thereof.

The invention provides a nucleic acid molecule for treating peripheral artery diseases of lower limbs and encoding multiple angiogenesis factors, a pharmaceutical composition and application of the nucleic acid molecule. Compared with the prior art, the pharmaceutical composition for treating the peripheral artery diseases of the lower limbs, provided by the invention, can remarkably promote angiogenesis of the lower limbs and improve ischemia of the lower limbs.

Disclosed herein are engineered nucleases and nuclease systems, including chimeric nucleases and chimeric nuclease systems. The engineered nucleases and chimeric nucleases disclosed herein include nucleic acid-guided nucleases. Additionally, disclosed herein are methods of producing and using the engineered nucleases.

The present disclosure relates to a polypeptide, an RNA molecule and a medical use thereof, and specifically relates to an ANGPTL polypeptide, an RNA molecule, a polynucleotide, a vector, lipid nanoparticles, a pharmaceutical composition and a medical use thereof.

Provided are a nucleic acid molecule encoding a plurality of angiogenesis factors and a pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb, and use thereof. Relative to the prior art, the pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb can significantly promote lower limb angiogenesis and improve lower limb ischemia.

Methods of determining the severity of an infectious disease, including ruling in sepsis, based on expression level of ANG-2.

The present disclosure provides a carrier protein for improving properties of a bioactive protein. The carrier protein has a G-X-Y ternary repetitive structure, G is glycine, and X and Y are independently selected from proline, alanine and glutamic acid. The present disclosure further provides a fusion protein containing the carrier protein and the bioactive protein. The fusion protein of the present disclosure has improved biological properties, such as improved pharmacokinetic and physicochemical properties.

The invention belongs to the technical field of biological medicines, and particularly relates to an osteoarthritis and rheumatoid arthritis mRNA (messenger Ribonucleic Acid) medicine and application. Specifically, a protein factor mRNA capable of stimulating cartilage proliferation and a protein factor mRNA capable of reducing cartilage cell inflammatory response are successfully prepared, and after the pharmaceutical preparation for osteoarthritis and rheumatoid arthritis is delivered into target cells, proliferation of cartilage cells and generation of extracellular matrixes can be promoted, and the inflammatory response of the cartilage cells can be reduced. The pathological processes of osteoarthritis and rheumatoid arthritis can be effectively reversed; the preparation method of the pharmaceutical preparation for arthritis is simple, convenient and rapid, the expression quantity of active ingredients is high, the immunogenicity is low, and bone articular cartilage growth can be rapidly and effectively promoted, so that the purpose of treating osteoarthritis and rheumatoid arthritis is achieved, and the pharmaceutical preparation has good practical application value.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

The present disclosure relates to productive tissue repair and regeneration, and in particular fusion proteins and polypeptides, compositions including said fusion proteins and polypeptides, and methods of using said polypeptides or compositions for productive tissue repair and regeneration. In one aspect, there is provided a fusion protein comprising (i) a calcitonin gene-related peptide (CGRP) receptor agonist polypeptide; and (ii) an extracellular matrix (ECM) binding polypeptide. In another aspect, there is provided a fusion protein comprising: (a) a first polypeptide; and (b) a second polypeptide, wherein the first and second polypeptide are joined by a linker that comprises, consists essentially of or consists of the amino acid sequence KGYR (SEQ ID NO: 70).

The present application belongs to the field of biotechnology, and relates to a method for expressing vascular endothelial growth factor by a gel type wheat germ cell-free protein system and application. The present application selects carboxymethyl chitosan and hyaluronic acid as raw materials, and after formula optimization of mechanical and biocompatibility parameters, the components of the cell-free protein synthesis system are integrated into the double network architecture, forming a system capable of realizing sustained vascular endothelial growth factor expression through encapsulated mRNA synthesis, which effectively relieves the burst toxicity, and realizes controlled treatment delivery. In addition, the open nature of the cell-free protein synthesis system allows programmable biosynthesis according to nucleic acid templates, thereby expressing various functional proteins, which greatly expands the potential of its transformation application.

The invention provides Ang1A451D antibody fusion protein equivalent to the function of Ang1A451D protein, and a production and purification technology and application of the Ang1A451D antibody fusion protein. According to the present invention, the Ang1A451D full-length protein is improved, and the Ang1-RBDA451D protein is fused with the Fc region of the human antibody IGg1, such that the protein expression is easy, and the purification cost is reduced; compared with the existing Ang1A451D production and purification technology, the method has the advantages of low production cost and higher protein yield.

The invention discloses a polypeptide and application thereof, and relates to the technical field of biology. The amino acid sequence of the polypeptide is shown as SEQ ID NO: 1. The polypeptide designed based on the precise binding site of the Gabp alpha and the Ppargamma comprises an aa164-189 amino acid sequence fragment of the Ppargamma, ARG168 and LYS184 sites can be specifically bound with ASP332 and GLN324 sites of the Gabp alpha respectively, a natural binding interface of the Gabp alpha and the Ppargamma can be competitively occupied, specific blocking of the interaction of the Gabp alpha and the Ppargamma is achieved, and the effect of inhibiting the Gabp alpha and the Ppargamma is achieved. Non-specific interference caused by interaction of other proteins is avoided, and a high-specificity tool is provided for targeted regulation of a brown adipose tissue related metabolic process.

The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

The invention belongs to the technical field of biology, and relates to a method for expressing a vascular endothelial growth factor through a gel type wheat germ cell-free protein system and application. According to the invention, carboxymethyl chitosan and hyaluronic acid are selected as raw materials, after formula optimization of mechanical and biocompatibility parameters, cell-free protein synthesis system components are integrated into the dual-network architecture to form a system capable of realizing continuous expression of the vascular endothelial growth factor through synthesis of encapsulated mRNA, and the cell-free protein synthesis system can be used for preparing the vascular endothelial growth factor. This effectively alleviates burst toxicity while achieving controlled therapy delivery. Furthermore, the open nature of the cell-free protein synthesis system allows programmable biosynthesis according to nucleic acid templates, thereby expressing various functional proteins, which greatly expands its potential of transformation applications.

The present disclosure relates to systems for prime editing and methods of use thereof. The present disclosure provides systems in which prime editing components are split between two expression cassettes in two vectors. The present disclosure further provides cardiac-specific promoters and expression cassettes in which a cardiac-specific promoter is operably linked to one or more prime editing component.

Provided herein are methods for assaying the chondrogenic inducing activity of therapeutic agents by measuring the expression and / or secretion levels of chondrogenic biomarkers.

A fusion protein or an antigen-binding fragment or domain thereof comprises a pair of heavy chain and light chain of a VEGF antibody, a pair of heavy chain and light chain of an IL-6 or IL-6R antibody, and a single domain antibody or a binding polypeptide directed against Ang-2 that is linked to each of the VEGF antibody and the IL-6 or IL-6R antibody.